Rate of Patient-Driven Biologic Treatment Discontinuation During the COVID-19 Pandemic in 2 Academic Hospital Clinics at the University of Toronto

Abstract

Keywords

COVID-19 psoriasis biologics dermatology

Get full access to this article

View all access options for this article.

References

Warren

RB.

Gooderham

Burge

et al. Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis. J Am Acad Dermatol. 2020;82(5):1138-1149.doi:10.1016/j.jaad.2019.12.038

http://www.ncbi.nlm.nih.gov/pubmed/31884091

Kim

HJ.

Lebwohl

MG.

Biologics

LMG

. Biologics and psoriasis: the beat goes on. Dermatol Clin. 2019;37(1):29-36.doi:10.1016/j.det.2018.07.004

http://www.ncbi.nlm.nih.gov/pubmed/30466686

Lebwohl

Rivera-Oyola

Murrell

. Should biologics for psoriasis be interrupted in the era of COVID-19? J Am Acad Dermatol. 2020;82(5):1217-1218.doi:10.1016/j.jaad.2020.03.031

32199889

Lee

Kovarik

Tejasvi

Pizarro

Lipoff

. Telehealth: helping your patients and practice survive and thrive during the COVID-19 crisis with rapid quality implementation. J Am Acad Dermatol. 2020;82(5):1213-1214.doi:10.1016/j.jaad.2020.03.052

32229278